Ovarian Cancer Trial, Recruiting NCT01601171 Sponsor: Centre Hospitalier Universitaire Vaudois Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT01601171
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with hypogonadotropic hypogonadism (a condition where the body does not produce enough sex hormones due to problems with signalling from the brain)
  • People diagnosed with Kallmann syndrome (a condition that delays or prevents puberty and affects the sense of smell)
  • People diagnosed with adult-onset hypogonadotropic hypogonadism (the same type of hormone signalling problem that develops in adulthood)
  • People diagnosed with hypothalamic amenorrhea (absent periods caused by a problem in a part of the brain called the hypothalamus)
  • People diagnosed with polycystic ovarian syndrome (PCOS)
  • People diagnosed with primary gonadal failure (where the reproductive organs do not work properly)
  • People diagnosed with precocious puberty (puberty that begins unusually early)
  • People diagnosed with cleft lip or cleft palate
  • Family members of people in any of the groups listed above

Who may not be able to join:

  • People who are currently seriously ill or hospitalised
  • People who have a tumour on the pituitary gland (a small gland at the base of the brain)
  • People with iron overload, also known as hemochromatosis (a condition where too much iron builds up in the body)
  • People with certain diseases that cause inflammation in organs, such as sarcoidosis (confirm with trial site)
  • People with a history of long-term heavy alcohol use
  • People who use illicit (illegal) drugs
  • People who misuse anabolic steroids (substances sometimes used to build muscle)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nelly Pitteloud, M.D., Centre Hositalier Universitaire Vaudois (CHUV)

Phone: +41 79 556 60 13

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire Vaudois
Registry
ClinicalTrials.gov
Start date
1 March 2012
Est. completion
1 March 2025

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

rare sequence variant(s) in gene(s)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov